Transcription of Lynparza Full Prescribing Information
{{id}} {{{paragraph}}}
Example: dental hygienist
Lynparza Full Prescribing Information
US-54700. HIGHLIGHTS OF Prescribing Information Prostate cancer These highlights do not include all the Information needed to use Lynparza safely for the treatment of adult patients with deleterious or suspected deleterious germline and effectively. See full Prescribing Information for Lynparza . or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior Lynparza (olaparib) tablets, for oral use treatment with enzalutamide or abiraterone. Select patients for therapy based on an Initial Approval: 2014 FDA-approved companion diagnostic for Lynparza .
m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: